{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCD&page=13",
    "query": {
      "intervention": "PCD",
      "page": 13
    },
    "page_size": 10
  },
  "pagination": {
    "page": 13,
    "page_size": 10,
    "total_count": 456,
    "total_pages": 46,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCD&page=14&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=PCD&page=12&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T00:42:05.753Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03848182",
      "title": "Analyzing Childhood Recall Antigens in Patients With Pancreatic Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "TT vaccine booster",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 10,
      "start_date": "2017-07-21",
      "completion_date": "2019-11-11",
      "has_results": true,
      "last_update_posted_date": "2024-04-18",
      "last_synced_at": "2026-10-23T00:42:05.753Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03848182"
    },
    {
      "nct_id": "NCT03284424",
      "title": "Study of Pembrolizumab (MK-3475) in Adults With Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) or Locally Advanced Unresectable cSCC (MK-3475-629/KEYNOTE-629)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 159,
      "start_date": "2017-10-26",
      "completion_date": "2023-09-13",
      "has_results": true,
      "last_update_posted_date": "2024-08-23",
      "last_synced_at": "2026-10-23T00:42:05.753Z",
      "location_count": 14,
      "location_summary": "La Jolla, California • Palo Alto, California • Santa Rosa, California + 11 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03284424"
    },
    {
      "nct_id": "NCT07288827",
      "title": "Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Primary Ciliary Dyskinesia",
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Lung Function Testing",
          "type": "PROCEDURE"
        },
        {
          "name": "Phlebotomy",
          "type": "PROCEDURE"
        },
        {
          "name": "Allergy skin prick testing",
          "type": "PROCEDURE"
        },
        {
          "name": "Methacholine Challenge",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Indiana University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2023-05-04",
      "completion_date": "2028-04-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-10-23T00:42:05.753Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07288827"
    },
    {
      "nct_id": "NCT04084951",
      "title": "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Solid Tumor"
      ],
      "interventions": [
        {
          "name": "SQZ-PBMC-HPV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "SQZ Biotechnologies",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2020-01-28",
      "completion_date": "2023-02-09",
      "has_results": false,
      "last_update_posted_date": "2023-04-14",
      "last_synced_at": "2026-10-23T00:42:05.753Z",
      "location_count": 10,
      "location_summary": "Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04084951"
    },
    {
      "nct_id": "NCT03790488",
      "title": "Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "JTX-4014",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jounce Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2018-12-06",
      "completion_date": "2023-02-28",
      "has_results": false,
      "last_update_posted_date": "2023-07-03",
      "last_synced_at": "2026-10-23T00:42:05.753Z",
      "location_count": 4,
      "location_summary": "Denver, Colorado • Sarasota, Florida • Grand Rapids, Michigan + 1 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03790488"
    },
    {
      "nct_id": "NCT05082610",
      "title": "A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Tumor, Solid",
        "Nonsmall Cell Lung Cancer",
        "Triple Negative Breast Cancer",
        "Malignant Neoplasm",
        "Metastatic Cancer",
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "HMBD-002",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hummingbird Bioscience",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2022-02-28",
      "completion_date": "2024-12-03",
      "has_results": false,
      "last_update_posted_date": "2025-10-16",
      "last_synced_at": "2026-10-23T00:42:05.753Z",
      "location_count": 6,
      "location_summary": "Duarte, California • Los Angeles, California • Palo Alto, California + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05082610"
    },
    {
      "nct_id": "NCT06896188",
      "title": "9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Retifanlimab",
          "type": "DRUG"
        },
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "9-ING-41",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anwaar Saeed",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2025-09-22",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-24",
      "last_synced_at": "2026-10-23T00:42:05.753Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06896188"
    },
    {
      "nct_id": "NCT00079300",
      "title": "Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-melanomatous Skin Cancer"
      ],
      "interventions": [
        {
          "name": "imiquimod",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Naval Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2004-01",
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2013-04-26",
      "last_synced_at": "2026-10-23T00:42:05.753Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00079300"
    },
    {
      "nct_id": "NCT04221945",
      "title": "Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Uterine Cervical Neoplasms"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo for pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "External Beam Radiotherapy (EBRT)",
          "type": "RADIATION"
        },
        {
          "name": "Brachytherapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1060,
      "start_date": "2020-05-12",
      "completion_date": "2026-01-26",
      "has_results": true,
      "last_update_posted_date": "2026-02-20",
      "last_synced_at": "2026-10-23T00:42:05.753Z",
      "location_count": 28,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 25 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04221945"
    },
    {
      "nct_id": "NCT05208944",
      "title": "THIO Sequenced With Cemiplimab in Advanced NSCLC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "6-Thio-2'-Deoxyguanosine",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Maia Biotechnology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 227,
      "start_date": "2022-06-08",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-10-23T00:42:05.753Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Florham Park, New Jersey",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Florham Park",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05208944"
    }
  ]
}